-
October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
31 Mar 2025 19:52 GMT
… or more antidepressant(s)
Discontinuation-emergent cataplexy
FDA is evaluating … agonists
Adlyxin (lixisenatide) injection
Bydureon (exenatide) for extended-release injectable … information about hepatotoxicity.
An FDA Drug Safety Communication was issued on …
-
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
26 Mar 2025 11:30 GMT
… to guarantee medication adherence and potentially improve treatment tolerability … information becomes available. Bydureon BCise® is a … including those taking daily pills. Medication non-adherence, which … ’s planned clinical trials and the results therefrom …
-
Vivani treats first patient with long-lasting drug implant for weight loss
13 Mar 2025 17:43 GMT
… for type 2 diabetes treatment.
Shares in the Nasdaq … Vivani says the drug has demonstrated good drug release both in … ’s branded exenatide medication for diabetes Bydureon BCise, or weekly … dominant forces in the pharmaceutical sector. Wegovy is forecast …
-
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
13 Mar 2025 11:54 GMT
… treatment has demonstrated, or will demonstrate, clinical benefit.
Bydureon … designed to deliver drug molecules steadily over … including those taking daily pills. Medication non-adherence, which … ’s planned clinical trials and the results therefrom …
-
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
13 Mar 2025 11:21 GMT
…
Also Read: EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation … smooth and minimally fluctuating drug release in vitro and … =8), weekly exenatide injections (Bydureon BCise, n=8), or weekly … for which GLP-1 treatment has demonstrated or will …
-
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial
07 Feb 2025 18:46 GMT
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow … UK led the Exenatide-PD3 trial (NCT04232969), which sought to … UPDRS) whilst off Parkinson’s medication. At 96 weeks, MDS- … disorders. Research by the Clinical Trials Arena found that in 2024 …
-
April - June 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
05 Mar 2025 21:57 GMT
… and “Medication Guide” sections of the labeling for Adlyxin, Bydureon, Bydureon BCise, Byetta … hypertension.
Ocaliva labeling
An FDA Drug Safety Communication for Ocaliva was … intravenous infusion bags.
An FDA Drug Safety Communication on vinca alkaloids …
-
January - March 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
05 Mar 2025 21:57 GMT
…
Bridion labeling
Bydureon (exenatide)
Bydureon BCise (exenatide)
Byetta … Counseling Information,” and “Medication Guide,” sections of the …
Methylphenidate hydrochloride
Drug interaction between … Example: Inlyta labeling
FDA determined that no …
-
GLP-1 Analogues Market To Reach $471.1 Billion By 2032: A Major Shift In Diabetes Treatment
06 Mar 2025 01:57 GMT
… players offering GLP-1 drugs, favorable regulatory scenario … long term adherence to treatment by patients.
Ozempic ( … injection), Zepbound (tirzepatide), Bydureon (exenatide extended-release), and … UK), and Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (China) …
-
Lessons Learned From Vivani Medical's Study Of GLP-1 Implant
05 Mar 2025 14:49 GMT
… of doses and medication adherence on assessing drug efficacy and safety … specific purpose in the trial design. Bydureon BCise is the only … with the standard of care treatment. Furthermore, this design … frequent engagement with the FDA to optimize our clinical …
About
© 1995-2025